MP-1032 is under clinical development by MetrioPharm and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MP-1032’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MP-1032 overview
MP-1032 is under development for the treatment of moderate to severe chronic plaque psoriasis, rheumatoid arthritis, multiple sclerosis, sepsis, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Duchenne muscular dystrophy, amyotrophic lateral sclerosis(ALS) and other infectious, juvenile idiopathic arthritis, multiple influenza virus infections and acute respiratory distress syndrome. The drug candidate is administered through the oral route as a hard gelatin capsule, inhalational route and intravenous route. It is an agent from the MP1000 class. MP1000 is a platform of small molecular immune modulators with potent anti-inflammatory and anti-infective properties.
It was also under development for arthrosis and tendinopathy, severe burns, osteoarthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, Alzheimer's disease, atherosclerosis, non infectious uveitis, type II diabetes.
MetrioPharm overview
MetrioPharm is a clinical stage pharmaceutical biotech company that focuses on the development of new medications against inflammatory and infectious diseases. The company’s pipeline products include MP1032, that is developed to treat diseases such as duchenne muscular dystrophy, juvenile idiopathic arthritis, COVID-19, psoriasis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. The company operates through its research facility Germany and Switzerland. MetrioPharm is headquartered in Zurich, Switzerland.
For a complete picture of MP-1032’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
